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Abstract 
Background: Atrial fibrillation occurs frequently after open-heart surgery. It is associated 
with increased morbidity and mortality, longer hospital stays, and increased healthcare 
costs. Prophylactic administration of colchicine may mitigate post-operative atrial fibrillation 
(POAF).  
Methods: We searched PubMed, ClinicalTrials.gov and CENTRAL databases to identify 
randomized controlled trials (RCTs) that; (1) compared prophylactic use of colchicine to 
placebo, or usual care, in patients with sinus rhythm who underwent elective open-heart 
surgery and (2) reported POAF-incidence. We excluded trials focused on incidence of atrial 
fibrillation after percutaneous interventions or colchicine treatment of diagnosed pericarditis 
or post-pericardiotomy-syndrome. A random-effects model was used to pool data for POAF-
incidence as the primary outcome and for drug-related adverse effects, major adverse 
events (death and stroke), and hospital length-of-stay as secondary outcomes. 
Results:  We included five RCTs (1,412 patients). Colchicine treatment reduced POAF-
events by 30% versus placebo or usual care (18% vs. 27%, risk ratio (RR) 0.69, 95% 
confidence interval (CI) 0.57 to 0.84, p=0.0002). Adverse drug-related effects, especially 
gastrointestinal intolerance, increased with colchicine; (21% vs. 8.2%, RR 2.52, 95% CI 1.62 
to 3.93, p<0.0001). However, major adverse events were unchanged (3.2% vs 3.2%, RR 
0.96, 95% CI 0.48 to 1.95, p=0.92). Length-of-stay decreased by 1.2 days with colchicine 
(95% CI -1.89 to -0.44, p=0.002). 
Conclusion: Colchicine demonstrated superior efficacy versus usual care for prevention of 
atrial fibrillation after cardiac surgery. Moreover, colchicine treatment was associated with 
shorter hospital stays. These benefits outweigh increased risk of adverse drug-related 
effects; although further work is needed to minimize gastrointestinal effects. 
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1. Introduction  
 Post-operative atrial fibrillation (POAF) is a frequent complication of cardiac surgery. 
POAF occurs in 25-40% of coronary artery bypass graft (CABG) surgeries and 50-60% of 
valve surgeries.[1-3] POAF differs from non-valvular AF because it is usually transient, often 
resolves without treatment, is generally limited to the hospital stay, and rarely develops into 
a chronic condition.[4-5] Nevertheless, POAF is associated with increases in morbidity and 
mortality, hospital length-of-stay, and healthcare costs.[4,6-8] The annual financial burden of 
POAF in the United States is estimated to exceed 1 billion dollars. [3,9] 
 POAF development is multifactorial and probably involves; (1) surgically-created 
structural substrates for electrical re-entry pathways or ectopic activity, (2) pericardial 
inflammation, (3) excess catecholamine production, and (4) increased sympathetic 
tone.[3,10] Consequently, many studies evaluated POAF reduction strategies; including 
prophylactic administration of antiarrhythmic agents, heart-rate control drugs, and anti-
inflammatory agents.[10-12] Of these, beta-blockade is currently indicated and amiodarone 
is suggested for high-risk patients.[13] Recent American guidelines for managing AF suggest 
colchicine might also be considered to treat cardiac POAF; but, with only weak 
recommendation (CLASS IIb, Level of evidence B).[13] Nevertheless, because colchicine 
possesses both anti-inflammatory properties and sympatholytic activity, it appears a logical 
candidate for POAF therapy. Although colchicine reduced early AF recurrence after 
pulmonary vein isolation [14], its narrow therapeutic range and frequent gastrointestinal 
intolerance are disadvantages.[15] 
 Recent meta-analyses have drawn opposing conclusions regarding colchicine’s 
efficacy in POAF reduction.[16-19] Discrepancies probably occurred because these 
analyses used different inclusion criteria, different procedures, and assessed outcomes at 
different times. Therefore, our systematic review and meta-analysis focussed on a specific 
outcome with a specific time-frame in response to a specific injury; i.e., AF incidence early 
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after open-heart surgery in adults. Secondary endpoints were colchicine’s effect on hospital 
length-of-stay (LOS), drug-related adverse effects, and major adverse events.  
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2. Methods 
2.1. Search parameters 
 The study followed PRISMA-guidelines.[20] We searched PubMed, ClinicalTrials.gov, 
and CENTRAL databases to July 2016. The search terms for PubMed were; “atrial 
fibrillation”, or “Afib”, or “AF”, or “atrial”, or “supraventricular tachycardia”, or “arrhythmia” 
combined with “colchicine” (Appendix Table 1). For the other databases, the only search 
term was “colchicine”. No restriction regarding language or publication year was applied. 
 Identified articles were independently screened at the title and abstract level for 
pertinence by three investigators. Potential studies were retrieved as full-length papers and 
examined for inclusion based on the following predetermined criteria: only RCTs, 
comparison of the colchicine’s prophylactic use versus placebo, or usual care, in patients in 
sinus rhythm who underwent elective open-heart surgery and where the occurrence of 
POAF was reported. We defined “usual care” to mean continuation of established 
medication (including beta-blocker, ACE-inhibitors and angiotensin receptor-blockers). 
Open-heart surgery included CABG, valve surgery, aortic surgery, and any combination. 
Furthermore, any colchicine dose and treatment regime were accepted. However, we 
excluded colchicine trials focused on AF prevalence after interventions performed via 
vascular access (e.g., pulmonary vein isolation and left atrial appendage occlusion) or 
treatment of pericarditis and post-pericardiotomy-syndrome.  Any disagreements that arose 
during this process were resolved by discussion among coauthors. 
2.2. Data extraction 
 We extracted information on study design, population characteristics, treatment 
details, and outcomes and results (Appendix Table 2).  If available, we also examined the 
‘design description papers’ of included trials to obtain additional details.[21,22] Information 
was extracted using a defined data-extraction form independently by two researchers. The 
primary outcome was the risk ratio (RR) of the incidence of POAF. Secondary outcomes 
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were the difference in LOS, drug-related adverse effects, and major adverse events (death 
and stroke). Drug-related adverse events included; gastrointestinal intolerance (diarrhea, 
nausea, cramping, abdominal pain or vomiting), alopecia, anorexia, hepatotoxicity, 
myotoxicity, and bone marrow toxicity. [12,23,24] One study also reported the incidence of 
post-operative infection; although the exact nature of the infections was unspecified.[25] 
2.3. Risk of bias 
 We assessed risk of bias; i.e., flaws in study design, conduct, analysis, and 
reporting.[26] Whenever possible, quality assessment included trial registration protocols 
and study-design publications.[21,22] Information was extracted on; (1) random sequence 
generation, (2) allocation concealment, (3) blinding of participants and personnel and also 
outcome assessment, (4) incomplete outcome data - did investigators report completeness 
of outcome data for POAF; including participant attrition and exclusion of participants from 
analysis and the use of intention-to-treat analysis, (5) selective reporting, and (6) deviations 
between study protocols and reported outcomes.[27]  
2.4. Statistics 
 Categorical variables are presented as percentages and continuous variables as 
mean ± standard deviation (SD). Risk ratios (RR) were used for binary outcomes and mean 
difference was used for LOS; both with their 95% confidence intervals (CI). The pooled RR 
was calculated using a random effects model; DerSimonian-Laird method.[28] We also 
calculated the absolute risk reduction or absolute risk increase and the corresponding 
number needed to treat (NNT) or number needed to harm (NNH).  
 To assess heterogeneity, we applied the Cochrane Q-statistic [27] and assessed 
inconsistency using the I2-statistic.[29] We also assessed potential publication and reporting 
bias. 
 Statistical analysis was performed using ReviewManager software (Version 5.3.0.) 
and Stata (12.1; StataCorp, College Station, TX). 
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3. Results 
3.1 Search 
 Results are shown in Appendix Figure 1. Six RCTs were reviewed for eligibility and 
five included. [12, 23-25,30] One paper written in Farsi (with an English abstract) was 
translated using online tools and checked by a cardiologist who was a native Farsi-speaker. 
3.2. Study characteristics 
 Table 1 summarizes study and intervention characteristics of the RCTs. In total, 
1,412 patients were enrolled; 707 received colchicine around the time of open-heart surgery 
and 705 received standard treatment (control group). All studies used a colchicine 
maintenance-dose of 0.5 mg twice daily; however, treatment varied with respect to initiation 
time, loading-dose, and duration. Colchicine was used for one week in END-AF and in 
Sarazeem et al. [30] versus one month in both COPPS trials (Table 1). Follow-up ranged 
from one week to three months. Two RCTs measured POAF only after CABG [25,39], 
whereas the other three (COPPS, COPPS-2 and END-AF) enrolled patients after valve 
surgery or combined valve and CABG surgery [12,23,24]. Atrial fibrillation was diagnosed 
objectively either by continuous ECG monitoring or by 12-lead ECG-recording. Appendix 
Table 3 provides baseline patient characteristics. 
3.3. Risk of within-study bias 
 The risk-of-bias summary is presented in Appendix Figure 2 (for detailed assessment 
see Appendix Table 4). All studies used true random processes to generate study groups; 
but, only two studies provided information on allocation concealment. [23,24] Three studies 
were double blinded, while two used open-label design.[12,25] No study showed evidence of 
bias from incomplete data. Three studies specified intention-to-treat analysis.[23,24,30] No 
study reported >5% randomized patients with missing outcome data; however, in one, the 
proportion of excluded patients was unclear.[30] Two RCTs (Sarzaeem et al., Zarpelon et 
al.) were not registered, no study protocol was available, and so deviation between pre-
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specified and reported outcomes was not assessed.[25,30]  The incidence of POAF was not 
a pre-specified endpoint of the COPPS trial, thus reporting bias is possible. All other studies 
specified POAF incidence as a pre-specified primary or secondary endpoint. 
3.4. Meta-Analysis 
 Because the studies differed in colchicine treatment regime, length of follow-up, and 
type of surgery, different effect sizes might be anticipated. Therefore, we used random 
effects models to assess all parameters. 
3.5. POAF incidence and risk:  
 In controls, POAF incidence ranged from 13% to 42%.  Peri-operative colchicine 
therapy was associated with a reduction of >30% in POAF risk (RR 0.69, 95% CI 0.57 to 
0.84, p=0.0002, I2=1%; Figure 1); 18% (128/707) who received colchicine experienced 
POAF versus 27% (189/705) of control patients. The forest plot was arranged in order of 
increasing proportion of CABG-only cases. CABG-only surgeries accounted for 32% of the 
COPPS-2 trial, 50% in the COPPS trial, and 69% in END-AF. [12, 23, 24] In contrast, two 
RCTs included only CABG surgery.[19,30] All studies were relatively comparable in size. 
Individually, three studies failed to show differences between colchicine treatment and usual 
care. 
3.6. Drug-related adverse effects:  
 The reported drug-related adverse effects included all forms of gastrointestinal (GI) 
intolerance and all other reported adverse effects. The pooled data from four studies 
resulted in a 2.5-fold increased risk for all adverse effects for colchicine-treated patients 
versus placebo or usual care (RR 2.52, 95% CI 1.62 to 3.93, p<0.0001, I2=46%). In the 
colchicine group, 21% (126/599) experienced adverse effects versus 8% (49/597) of controls 
(Figure 2A). 
 Colchicine use is often limited because of GI intolerance. In a sub-group analysis, 
we separated GI distress (Figure 2B) from other drug-induced adverse effects (Figure 2C). 
 10 
 
The pooled data revealed colchicine treatment was associated with a 2.8-fold increased risk 
for gastrointestinal distress versus controls (Figure 2B), whereas there was only weak 
evidence for a difference in non-GI adverse effects (Figure 2C). 
3.7. Major adverse events:  
 Four trials (COPPS, COPPS-2, END-AF and Zarpelon et al.) reported major adverse 
events (death and stroke), while one (END-AF) limited this definition to death. The overall 
incidence of major adverse events was low; 3% in both groups; (19/599) for colchicine and 
(19/597) for controls (RR 0.96, 95% CI 0.48 to 1.95, p=0.92, I2=12%). There was no 
evidence against the null hypothesis of no difference between colchicine and control (Figure 
3). 
3.8. Hospital length-of-stay:  
 LOS was reported in three trials.[23,25,30] Colchicine treatment was associated with 
a one-day reduction in LOS (mean difference -1.2 days, 95% CI -1.9 to -0.4, p=0.002, 
I2=43%) (Figure 4). 
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4. Discussion 
 Colchicine reduced the incidence of atrial fibrillation early after cardiac surgery by 
30% and reduced hospital length-of-stay by approximately one day. Moreover, colchicine 
therapy was not associated with increased mortality or stroke. However, we found a greater 
than two-fold increase in side-effects; specifically, gastrointestinal intolerance. 
 The hypothesis was that by restricting assessment of colchicine’s potential benefit to 
a specific outcome, time-frame, and injury, this would maximize the opportunity to determine 
colchicine’s efficacy against POAF and minimize potential confounding effects of 
incongruous study combinations. Previous, less focused, evaluation produced equivocal 
results. For example, a meta-analysis of colchicine for prevention of cardiovascular events 
examined long-term effects (39 RCTs; 4,992 participants; at least six-month follow-up).[31] 
Although for many parameters (including all-cause mortality, cardiovascular mortality, heart 
failure, and stroke; AF was not assessed) risk ratios were less than one (favoring colchicine), 
the 95% CIs crossed one. Similarly, there was no clear evidence to indicate increased risk of 
total adverse events with colchicine (the 95% CIs again crossed one). Only myocardial 
infarction exhibited benefit; RR = 0.28 [95% CI 0.07 to 0.57]. 
 Other colchicine-related meta-analyses combined short-term and long(er)-term 
studies, combined short-term RCTs likely to produce different degrees of inflammatory 
response (e.g., surgery and percutaneous intervention), or even combined studies with 
different outcomes (Appendix Table 5). Such approaches sometimes produced conflicting 
results and conclusions. For example, Wang et al. concluded colchicine had no effect on 
POAF.[18] However, they included an RCT designed to examine pericardial effusion that 
enrolled participants and began colchicine treatment 16 days after surgery with two RCTs 
that randomized participants either on day-three after surgery or two-to-three days prior to 
surgery. Because POAF typically occurs in the first week after surgery, we suggest such 
combination is invalid unless the question is, “can colchicine prevent AF at any time after 
surgery”.[32] Similarly, two meta-analyses combined the outcomes of POAF and AF 
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recurrence after pulmonary vein isolation for treatment of previous symptomatic AF.[17,33] 
Again, we suggest combination of different disease entities (non-valvular and post-surgery 
atrial fibrillation) and interventions (minimally invasive transvenous ablation and open-heart 
surgery) can mislead. 
 These examples emphasize that the specific question addressed in meta-analysis is 
a crucial determinant of the result. The eligibility criteria we applied were more discriminating 
than in the above-mentioned meta-analyses. In particular, outcomes and procedures were 
specified. Specificity restricts generalizability of results and conclusions; however, it does 
mean the results and conclusions apply unambiguously to colchicine as an early treatment 
to prevent AF after cardiac surgery. In addition, since publication of these meta-analyses, 
two additional RCTs have been published which increased the number of patients by 
500.[12,19] 
4.1.POAF reduction 
 The overall incidence of POAF decreased from 27% (189/705) to 18% (128/707) in 
colchicine-treated patients. This difference yielded a number-needed-to-treat of 11.5. Three 
of the studies found only weak evidence against the null hypothesis of no benefit of 
colchicine-associated protection against POAF (Figure 1). Two of these studies [12,25] were 
underpowered to detect the 30% reduction in POAF indicated by our meta-analysis. Both 
RCTs performed pre-study power-analysis; however, they assumed the AF incidence 
reduction would be 52% and 70% respectively. The third study was also underpowered to 
detect a 30% reduction in AF (70% power). Nonetheless, the pooled effect estimate provided 
strong statistical evidence of POAF reduction with colchicine treatment. 
 Numerous approaches to managing cardiac POAF have been used and these come 
with various classes of recommendation and levels of evidence.[32,33] Of these 
approaches, β-blockade is considered the foundation. A meta-analysis of 33 studies (4,698 
patients) found an odds ratio of 0.33 (95% CI 0.26 to 0.43) for POAF reduction with β-
blockers versus control.[34] In the three studies in our meta-analysis that reported β-blocker 
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use [23,25], more than 50% of patients in both groups received this treatment. Thus, the 
apparent protection conferred by colchicine seen in the current analysis may be in addition 
to β-blocker-mediated benefit. Only two studies reported data on amiodarone use and 
neither indicated any effect. 
4.2. Sensitivity Analysis 
 When we reanalysed the data, removing each study in turn (Appendix Figure 3), the 
overall risk ratio ranged from 0.59 [95% CI 0.45 to 0.77] (COPPS-2 omitted) to 0.73 [95% CI 
0.60 to 0.90] (Sarzaeem et al. omitted). Neither the point estimates nor the 95% CIs 
changed appreciably and so our interpretations are not dependent upon a single study. This 
was also true when the COPPS study was excluded. 
 Use of the DerSimonian-Laird method has been criticized because it can provide 
falsely precise estimates.[35] Two alternative methods for random effects models, the 
Knapp-Hornung and profile likelihood approaches have been recommended to reduce the 
risk of false positive conclusions.[36] When we applied these methods, colchicine still 
reduced POAF; Knapp-Hornung RR = 0.71 [95% CI 0.44 to 0.98] and profile likelihood RR = 
0.71 [95% CI 0.47 to 0.90]. Similarly, when we used a fixed effects model, there was no 
material change in the results; RR = 0.68 [95% CIs 0.56 to 0.82]).  
 There are, as far as we are aware, four ongoing RCTs (ISRCTN72835417, 
ACTRN12613001345774, NCT01985425 and NCT02177266).[17] These will add 
approximately 1,100 patients. We constructed a model and ran simulated meta-analysis that 
assumed each of these studies would produce results as unfavourable as the study currently 
indicating the smallest effect (COPPS-2; RR = 0.81; Figure 1).[37] With the added 
assumption that the incidence of AF in their control groups would equal the average of the 
five included studies (25%), the simulated RR was 0.74 (95% CI [0.65 to 0.86]) versus 0.69 
(95% CI [0.57 to 0.84] in the original analysis). If we assumed the incidence of AF in control 
groups increased to that of the maximum of the included studies (42%), the simulated RR 
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was 0.76 (95% CI [0.68 to 0.85]). Therefore, it appears unlikely additional studies will 
materially alter the results and, more importantly, the conclusion of our meta-analysis. 
 In summary, sensitivity analysis indicates the conclusion of colchicine’s benefit in 
POAF reduction is robust.  
4.3 Adverse effects of colchicine 
 Only three RCTs provided data on GI-related problems. The effect was large (RR = 
2.87; 95% CI [1.77 to 4.64]; Figure 2B), albeit with wide confidence intervals. This finding is 
consistent with other studies. In the previously mentioned meta-analysis of colchicine’s long-
term effects, the risk of gastrointestinal adverse events with colchicine was similarly 
increased (RR = 1.83; 95% CI 1.03 to 3.26). Increased risk was also reported in an RCT of 
colchicine’s effect on myocardial injury after CABG surgery (RR = 4.83; 60 patients, [38]) 
and in an RCT to examine the effect of colchicine on recurrent AF after pulmonary vein 
isolation (RR = 4.49; 206 patients, [36]). This is important because GI-related problems are 
often the reason for discontinuation of colchicine. 
 Only one RCT [25] reported infection as an adverse effect; the rate was 
approximately three times higher with colchicine than controls. There are at least two 
explanations. First, this finding may be related to colchicine’s action on immune response. 
[39] Second, colchicine’s anti-inflammatory properties may impair wound healing.[40] More 
data on this complication are required. 
 The lack of any effect on major adverse events, specifically death and stroke, is 
consistent with previous meta-analysis for several indications.[29,31] 
 In summary, colchicine therapy for POAF does not appear to result in major adverse 
events; however, GI problems are often severe and frequent enough to stop treatment. 
4.4. Bias 
 The risk of bias in the studies appears unlikely to have affected our conclusions. Two 
RCTs used open-label study design and both staff and patients were aware of treatment 
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allocation. We do not believe this source of bias influenced the primary outcome because AF 
was measured objectively; documented by holter-monitor or ECG-recording. However, if 
both open-labels studies were excluded, the benefit of colchicine remained; RR = 0.65 [95% 
CI 0.46 to 0.91; P = 0.01]. In contrast, for adverse events such as gastrointestinal 
intolerance, subjective judgement may play a role and thereby produce bias. 
With only five studies in the POAF analysis, there is insufficient data to yield robust 
statistical analysis of funnel plot asymmetry to assess publication bias. Nevertheless, current 
interest in the effect of colchicine on AF means negative studies are unlikely to be subject to 
publication bias; for example, although the study by Tabbalat et al. failed to show 
unequivocal benefit, it was published. 
4.5. Unanswered questions and future research  
 We demonstrated ongoing RCTs appear unlikely to alter the conclusion that 
colchicine reduces POAF (unless their results are considerably different from all of the 
previous RCTs). Nonetheless, these studies will be valuable. One potential use of meta-
analysis is to identify specific populations that might derive greater benefit from colchicine 
therapy. When we arranged the studies in the POAF forest plot in order of increasing 
proportion of CABG-alone surgeries (Figure 1), there was a shift towards greater effect size 
as the proportion of CABG-alone cases in the trial increased. That is, colchicine was more 
effective in reducing the incidence of AF in studies with the highest proportion of CABG 
cases. This is somewhat surprising because the incidence of POAF is typically lowest in 
CABG-only surgery. The small number of studies included in our meta-analysis precluded 
meta-regression and so confirmation of this potential relationship awaits the addition of more 
RCTs. Of the four registered, but unpublished, RCTs one is of CABG alone, two include 
CABG and aortic valve surgery, and one is for lung tumour resection. This distribution should 
enable any relationship between outcome effect and type of surgery to be determined. 
 Future studies may optimize therapy. Evidence indicates considerable variability in 
response to colchicine and the existence of ‘non-responders’.[39,44] Correlation of plasma 
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levels to treatment response may therefore provide a method of customized individual 
therapy. None of the ongoing RCTs indicated an intention to measure plasma levels. 
Nonetheless, inter-study differences in dose may provide insight. All studies in the meta-
analysis used 0.5 mg twice-a-day maintenance dose. In contrast, two of the unpublished 
trials, conducted in Canada and the United States, indicated they would use 0.6 mg twice-a-
day (the formulation currently available in North America). Will a 20% dose increase also 
increase the proportion of ‘responders’, thereby increasing efficacy, or will there just be more 
side-effects? Also, future research could determine whether colchicine dose reduction leads 
to reduction in gastrointestinal intolerance without diminished efficacy of POAF prevention. 
Gunda et al. found that “low dose”-colchicine (0.3 mg bid) reduced GI side-effects by 66% 
(4% vs. 12%) in patients after left atrial appendage ligation, but maintained efficacy, i.e., a 
lower incidence of severe pericarditis versus “high dose”-colchicine (0.6 mg bid).[45] The 
optimal outcome would be that lower colchicine doses remained efficacious, while adverse 
gastrointestinal events decreased. 
 The ongoing studies could also enable the COPPS trial to be replaced in this meta-
analysis. The trial is problematic because colchicine was started three days after surgery; 
even though POAF incidence peaks on day-two. Given the late treatment start, it is 
surprising COPPS had a more favourable effect than COPPS II in which therapy began 
before surgery. However, COPPS II included more valve surgery cases, fewer CABG cases, 
and 20% of patients discontinued therapy. These factors could explain the increased 
incidence of POAF in COPPS II. 
 As far as we are aware, there has been no cost-utility study conducted to assess 
colchicine and POAF. The estimated one-day reduction in LOS could produce considerable 
savings because colchicine treatment costs would be small (~2 Euros per day). However, 
this speculation is tempered because only three RCTs provided LOS data and a causal link 
with POAF treatment was not established. 
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5. Conclusion 
In conclusion, there is strong statistical evidence to support colchicine therapy to 
reduce POAF after open-heart surgery. Colchicine may also serve as a complementary 
strategy to the current recommended postoperative use of beta-blockade. Colchicine 
treatment for POAF has a current class IIb indication with level of evidence B.[13] The 
results of our meta-analysis, and specifically its robustness, prompt us to propose the 
recommendations be reassessed and upgraded to endorse prophylactic use of colchicine. 
Nevertheless, there remains scope for refinement of therapy through identification of 
populations and individuals who could derive greatest benefit and by optimizing therapy to 
minimize adverse gastrointestinal effects. 
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Figure 1: Forest Plot for risk ratio of post-operative atrial fibrillation. Individual and  
 pooled risk ratios with 95% confidence intervals for RCTs enrolling patients 
 undergoing open-heart surgery comparing colchicine therapy versus placebo 
 or usual care.   
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Figure 2:  (A) Forest plot for all drug-related adverse effects. Individual and pooled risk 
 ratios with 95% confidence intervals for RCTs enrolling patients undergoing open 
 heart surgery comparing colchicine versus placebo or usual care.  
 (B) risk ratio for colchicine-induced gastrointestinal adverse effects.  
 (C) colchicine-associated non-gastrointestinal adverse effects.  
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Figure 3: Major adverse events (death and stroke). Individual and pooled risk ratios 
  (RR) with 95% confidence intervals. 
 
 
 
 
Figure 4: Forest Plot for hospital length-of-stay. Mean difference with 95% confidence 
  intervals  
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Table 1: Study and intervention characteristics of the included randomized controlled trials 
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Appendix Figure 1:  Flow chart showing the search strategy and number of studies   
   screened, assessed, and included. 
   * search term limited to “colchicine” 
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Appendix Figure 2: Risk of bias assessments for included studies:   
   Plus/green suggests low of risk bias, question mark/yellow shows  
   uncertain risk of bias, minus/red indicates potential high risk of bias 
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Appendix Figure 3: Robustness-analysis (risk ratio and corresponding 95% confidence  
   interval) by removal of each individual study in turn (study named on  
   the left-hand side is omitted)  
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Appendix Table 1:  References identified in “PubMed” applying the described search terms.  
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Appendix Table 2:  Extracted parameters 
   POAF = post-operative atrial fibrillation, BMI = body mass index, AF = atrial fibrillation 
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Appendix Table 3: Baseline patient characteristics of the included randomized controlled trials 
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Appendix Table 4:  Quality and risk of bias assessment of included RCTs 
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Appendix Table 5:  Comparison of the present with prior published meta-analysis on Colchicine and the occurrence of atrial fibrillation after cardiac  
  procedure 
 
 
 
 
 
